Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125612851 | 12561285 | 1 | I | 20160709 | 20160715 | 20160715 | EXP | US-VIIV HEALTHCARE LIMITED-US2016GSK099409 | VIIV | 0.00 | Y | 0.00000 | 20160715 | CN | GB | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125612851 | 12561285 | 1 | PS | Maraviroc | MARAVIROC | 1 | UNK | 22128 | |||||||||||
| 125612851 | 12561285 | 2 | SS | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | UNK | 0 | |||||||||||
| 125612851 | 12561285 | 3 | SS | ISENTRESS | RALTEGRAVIR POTASSIUM | 1 | UNK | Y | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125612851 | 12561285 | 1 | HIV infection |
| 125612851 | 12561285 | 2 | HIV infection |
| 125612851 | 12561285 | 3 | HIV infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125612851 | 12561285 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125612851 | 12561285 | Blood HIV RNA increased | |
| 125612851 | 12561285 | Drug resistance | |
| 125612851 | 12561285 | Pathogen resistance |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125612851 | 12561285 | 3 | 201605 | 0 |